Literature DB >> 16550718

Effect of GH treatment on bone mass in children with GH deficiency.

G I Baroncelli1, G Saggese.   

Abstract

Children with GH deficiency have reduced bone mass and mineral density in comparison with normal individuals. GH treatment improves the accrual of bone mass during childhood and adolescence, but suboptimal GH treatment may cause a reduced bone mass in adulthood. At final height, treated patients with GH deficiency have normal mean values of bone mass, but some patients showed reduced lumbar bone mineral density (BMD) values. Lumbar peak bone mass (PBM) in treated patients who discontinued the treatment at final height is delayed and reduced. GH treatment during the transition from late adolescence to young adulthood can increase bone mass and mineral density. In patients with GH deficiency a possible strategy for avoiding acquisition of a suboptimal bone mass in the young-adult, could be to continue GH treatment during the transition to adulthood up to the acquisition of PBM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16550718

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  5 in total

1.  Medically underserved girls receive less evaluation for short stature.

Authors:  Adda Grimberg; Kristen A Feemster; Susmita Pati; Mark Ramos; Robert Grundmeier; Andrew J Cucchiara; Virginia A Stallings
Journal:  Pediatrics       Date:  2011-03-21       Impact factor: 7.124

2.  Reference equations for ultrasound bone densitometry of the radius in Central European children and adolescents.

Authors:  M J Scherrer; M K Rochat; D Inci; A Moeller
Journal:  Osteoporos Int       Date:  2014-07-16       Impact factor: 4.507

Review 3.  Pediatric DXA: clinical applications.

Authors:  Larry A Binkovitz; Paul Sparke; Maria J Henwood
Journal:  Pediatr Radiol       Date:  2007-04-13

4.  A follow-up study to monitor adult height among Spanish children with growth hormone deficiency who received biosimilar human recombinant growth hormone (Omnitrope®) during a phase III clinical trial.

Authors:  Victoria Borrás Pérez; Juan Pedro López-Siguero; Gabriela Martínez; Raquel Corripio; Juan Manuel Fernández; Jose Ignacio Labarta; Marta Ferrer; Nuria Cabrinety; Pablo Prieto; Marta Ramón-Krauel; Jordi Bosch; Rafael Espino; Margarida Palla Garcia; Francisco Jose Rebollo
Journal:  Adv Ther       Date:  2015-02-11       Impact factor: 3.845

5.  Growth Hormone and Craniofacial Tissues. An update.

Authors:  George Litsas
Journal:  Open Dent J       Date:  2015-01-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.